Global Broluzumab Biosimilars Market
As the global economy mends, the 2021 growth of Broluzumab Biosimilars will have significant chan ... Read More
As the global economy mends, the 2021 growth of Raibizumab Biosimilars will have significant change from previous year. According to our (LP Information) latest study, the global Raibizumab Biosimilars market size is USD million in 2022 from USD million in 2021, with a change of % between 2021 and 2022. The global Raibizumab Biosimilars market size will reach USD million in 2028, growing at a CAGR of % over the analysis period 2022-2028.
The United States Raibizumab Biosimilars market is expected at value of US$ million in 2021 and grow at approximately % CAGR during forecast period 2022-2028. China constitutes a % market for the global Raibizumab Biosimilars market, reaching US$ million by the year 2028. As for the Europe Raibizumab Biosimilars landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period 2022-2028. In APAC, the growth rates of other notable markets (Japan and South Korea) are projected to be at % and % respectively for the next 6-year period.
Global main Raibizumab Biosimilars players cover Roche, Novartis, Genentech, and Pfizer, etc. In terms of revenue, the global largest two companies occupy a share nearly % in 2021.
This report presents a comprehensive overview, market shares, and growth opportunities of Raibizumab Biosimilars market by product type, application, key manufacturers and key regions and countries.
Segmentation by type: breakdown data from 2017 to 2022, in Section 2.3; and forecast to 2028 in section 12.6
AMD
CNV
DME
Segmentation by application: breakdown data from 2017 to 2022, in Section 2.4; and forecast to 2028 in section 12.7.
ARMD
Diabetic Retinopathy
Macular Edema
This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The report also presents the market competition landscape and a corresponding detailed analysis of the prominent manufacturers in this market, include
Roche
Novartis
Genentech
Pfizer
Sartorius
Eli Lilly
Bayer
Amgen
PlantForm
PharmaPraxis
Samsung Bioepis
Centus
Cadila Pharmaceuticals
Dr Reddy's
Aurobindo Pharma
Biocad
MAbxience
Hetero
Biocon
Kirin Biologics
Mylan
BeiGene
Innovent
Qilu Pharmaceutical
Hengrui Pharmaceuticals
Hisun Pharmaceutical
TOT BIOPHARM
Luye Pharmaceutical
Henlius
As the global economy mends, the 2021 growth of Broluzumab Biosimilars will have significant chan ... Read More
As the global economy mends, the 2021 growth of Aflibercept Biosimilars will have significant cha ... Read More
As the global economy mends, the 2021 growth of Industrial Flavors and Fragrances will have signi ... Read More
As the global economy mends, the 2021 growth of Daily Chemical Flavors and Fragrances will have s ... Read More